Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: Results of the ERISAC randomized placebo-controlled trial

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1605-1612

  Bundred, Nigel J ^a   Cramer, Angela ^b   Morris, Julie ^a   Renshaw, Lorna ^c   Cheung, Kwok Leung ^d   Flint, Pamela ^b   Johnson, Rachael ^a   Young, Oliver ^c   Landberg, Göran ^b   Grassby, Sue ^a   Turner, Lorraine ^a   Baildam, Andrew ^a   Barr, Lester ^a   Dixon, J Michael ^c  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c Edinburgh Breast Unit   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; KI 67 ANTIGEN; PLACEBO; PROGESTERONE RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SURGERY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED HEADACHE; EPITHELIUM CELL; FEMALE; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY;

ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PLACEBOS; PYRAZOLES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SULFONAMIDES;

EID: 77649140377     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1623     Document Type: Article

References (20)

1. Dixon JM, Faratian D, White S, et al. DCIS and aromatase inhibitors. J Steroid Biochem Mol Biol 2007;106:173-9.
2. Boland GP, McKeown A, Chan KC, et al. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast. Br J Cancer 2003;89:277-83.
3. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer:national surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 1999;353:1993-2000.
4. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
5. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Systematic Reviews 2009;3, Art No.:CD000563. DOI: 10.1002/14651858. CD0000563, pub 3.
6. Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24. Breast Cancer Res Treat 2002, abstr 825.
7. Boland GP, Butt IS, Prasad R, et al. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004;90:423-9.
8. Chan KC, Knox WF, Gee JM, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 2002;62:122-8.
9. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/ neu. Breast Cancer Res Treat 1992;24:85-95.
10. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1 and/or ErbB2 positive, ER positive primary breast cancer. J Clin Oncol 2001;15:3808-16.
11. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
12. Brueggemeier RW, Díaz-Cruz ES, Li PK, et al. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol 2005;95:129-36.
13. Barnes NL, Warnberg F, Farnie G, et al. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 2007;96:575-82.
14. Dowsett M, Smith IE, Ebbs SR, et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res 2006;12:1024-30s.
15. Howe LR, Subbaramaiah K, Brown MA, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-114.
16. Wang SC, Lein HC, Xia W, et al. Binding at and transcriptional activation of COX-2 promotor by nuclear tyrosine kinase receptor ErbB2. Cancer Cell 2004;6:251-26.
17. Dirix LY, Ignacio J, Nag S, et al. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 2008; 26:1253-9.
18. Chow LW, Yip AY, Loo WT, et al. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;111:13-7.
19. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
20. Kimler BF, Fabian CJ, Anderson JR, et al. Breast cancer chemoprevention phase IB evaluation of biomarker modulation by celecoxib, a selective cyclooxygenase 2 inhibitor. San Antonio Breast Cancer Symposium. 2006, Abstr 1058.